DePriest A, Puet B, Heltsley R, Robert T, Black D. Uncertainty in assessing impact of drug-drug interactions on oxycodone metabolite patterns. J Anal Toxicol. 2014. In press.
Schwope D, DePriest A, Black D, Caplan Y, Cone E, Heltsley R. Determining zolpidem compliance: urinary metabolite detection and prevalence in chronic pain patients. J Anal Toxicol. 2014. In press.
Gordon A, Cone EJ, DePriest AZ, Axford-Gatley RA, Passik SD. Risks and responsibilities in using opioids for chronic noncancer pain: risk assessment. Postgrad Med. 2014. In press.
DePriest AZ, Black DL, Robert TA. Immunoassay in healthcare testing applications. J Opioid Manage. 2014. In press.
Knight J, Puet BL, DePriest AZ, Heltsley R, Hild C, Black DL, Robert T, Caplan YH, Cone EJ. Prevalence of heroin markers in urine for pain management patients. Forensic Sci Int. 2014;243:79-83.
DePriest AZ, Miller K. Oxycodone/naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence. Pain Ther. 2014. doi:10.1007/s40122-014-0026-2.
DePriest AZ, Miller K, Cone EJ. Buprenorphine: clinical use, abuse, and compliance monitoring. In: Bennet R, editor. Buprenorphine: Pharmacology, Clinical Uses and Potential Side Effects. Hauppauge, NY: Nova Science Publishers, Inc; 2014.